Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 4;6(1):1.
doi: 10.1186/s42466-023-00294-0.

Neuropathological hints from CSF and serum biomarkers in corticobasal syndrome (CBS): a systematic review

Affiliations
Review

Neuropathological hints from CSF and serum biomarkers in corticobasal syndrome (CBS): a systematic review

Giulia Remoli et al. Neurol Res Pract. .

Abstract

Corticobasal syndrome (CBS) is a clinical syndrome determined by various underlying neurodegenerative disorders requiring a pathological assessment for a definitive diagnosis. A literature review was performed following the methodology described in the Cochrane Handbook for Systematic Reviews to investigate the additional value of traditional and cutting-edge cerebrospinal fluid (CSF) and serum/plasma biomarkers in profiling CBS. Four databases were screened applying predefined inclusion criteria: (1) recruiting patients with CBS; (2) analyzing CSF/plasma biomarkers in CBS. The review highlights the potential role of the association of fluid biomarkers in diagnostic workup of CBS, since they may contribute to a more accurate diagnosis and patient selection for future disease-modifying agent; for example, future trial designs should consider baseline CSF Neurofilament Light Chains (NfL) or progranulin dosage to stratify treatment arms according to neuropathological substrates, and serum NfL dosage might be used to monitor the evolution of CBS. In this scenario, prospective cohort studies, starting with neurological examination and neuropsychological tests, should be considered to assess the correlations of clinical profiles and various biomarkers.

Keywords: CBS biomarkers; CBS neuropathology; Corticobasal syndrome; Dementia biomarkers; Fluid biomarkers.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
A PRISMA flow diagram of the study selection process

References

    1. Parmera JB, Rodriguez RD, Neto AS, Nitrini R, Brucki SMD. Corticobasal syndrome: A diagnostic conundrum. Dementia & neuropsychologia. 2016;10(4):267–275. doi: 10.1590/S1980-5764-2016DN1004003. - DOI - PMC - PubMed
    1. Koga S, Josephs KA, Aiba I, Yoshida M, Dickson DW. Neuropathology and emerging biomarkers in corticobasal syndrome. Journal of Neurology, Neurosurgery and Psychiatry. 2022;93(9):919–929. doi: 10.1136/JNNP-2021-328586. - DOI - PMC - PubMed
    1. Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: A pathologically distinct 4R tauopathy. Nature Reviews Neurology. 2011;7(5):263–272. doi: 10.1038/NRNEUROL.2011.43. - DOI - PMC - PubMed
    1. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916–919. doi: 10.1038/NATURE05016. - DOI - PubMed
    1. Benussi L, Binetti G, Sina E, Gigola L, Bettecken T, Meitinger T, Ghidoni R. A novel deletion in progranulin gene is associated with FTDP-17 and CBS. Neurobiology of Aging. 2008;29(3):427–435. doi: 10.1016/J.NEUROBIOLAGING.2006.10.028. - DOI - PubMed

LinkOut - more resources